Jump To Section
Featured Stories
Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell
Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020.
Job Cuts As Polyphor Focuses On First-In-Class Anticancer
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Asia Spotlight
China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Recent Tweets from Scrip
Outlook 2020
2020 Vision For Biopharma
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
Gene Therapy Manufacturers Are Highly Sought Acquisition Targets
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
GSK Partnership With Immatics Seeks TCR Therapeutics For Solid Tumors
Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.
Reverse Merger With Tocagen Takes Forte’s Dermatology Ambitions Public
Deal Snapshot: Forte finds a route to the public markets to support moving its atopic dermatitis drug into Phase II; most of Tocagen’s assets will be sold off.
Merck KGaA Tightens Focus With Allergopharma Sale
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Bharat Biotech Plans Coronavirus Vaccine
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
HLB Takes First Expansion Step Via Immunomic Acquisition
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Genfit Delays NASH Data While It Confers With US FDA On Methodology
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Interview: Novartis's Big Hopes For Beovu
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Teva’s Austedo Fails In Tourette’s Syndrome
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.